Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Petter Bjornstad

Pediatric Endocrinology Seattle, WA Medical Doctor

NPI 1023363751 CMS profile 2784377

1959 Ne Pacific St, Seattle, WA 98195

Open in the dashboard

General payments

$159,402

157 records reported · program years 2019–2025

Research payments

$49,291

Paid to them · 26 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,747,801 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Petter Bjornstad of Seattle, WA is reported in the CMS Open Payments database as having received $159,402 across 157 general payments and $49,291 in research payments paid to them. Separately, studies naming them as principal investigator received $2,747,801 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $39,837 26
2025 Research $30,254 12
2024 General $18,726 21
2024 Research $17,198 8
2023 General $35,190 42
2023 Research $1,839 6
2022 General $16,717 31
2021 General $10,397 10
2020 General $17,024 9
2019 General $21,511 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Petter Bjornstad
  • Pediatric Endocrinology median
  • Middle half of Pediatric Endocrinology
  • National median

In program year 2025, general payments to Petter Bjornstad were reported at $39,837. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.

Show as a table
Year Petter Bjornstad Pediatric Endocrinology median Middle half National median
2019 $21,511 $196 $68–$845 $163
2020 $17,024 $124 $37–$722 $114
2021 $10,397 $134 $35–$691 $132
2022 $16,717 $177 $47–$726 $149
2023 $35,190 $236 $75–$887 $160
2024 $18,726 $259 $91–$979 $164
2025 $39,837 $293 $106–$1,640 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Eli Lilly and Company $59,289 63 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $29,593 37 payments
  3. Novo Nordisk AS $24,130 19 payments
  4. Boehringer Ingelheim International GmbH $22,140 16 payments
  5. E.R. Squibb & Sons, L.L.C. $6,230 5 payments
  6. AstraZeneca UK Limited $4,833 1 payment
  7. Genzyme Corporation $3,441 2 payments
  8. AstraZeneca Pharmaceuticals LP $3,246 4 payments
  9. Roche Products Limited $2,763 1 payment
  10. Horizon Therapeutics plc $2,162 5 payments
  11. Other $1,575 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $121,501 116 payments
  2. Travel and Lodging $30,739 15 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,191 6 payments
  4. Honoraria $1,881 1 payment
  5. Food and Beverage $1,090 19 payments
Products named General payments · program years 2019–2025
  1. Kerendia $21,373 28 payments
  2. Ozempic $15,416 7 payments
  3. Adempas $8,220 9 payments
  4. TZIELD $3,473 3 payments
  5. JARDIANCE Diabetes $2,655 1 payment
  6. KRYSTEXXA $2,162 5 payments
  7. JARDIANCE Diabetes $1,242 4 payments
  8. TRULICITY $26 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Bayer HealthCare Pharmaceuticals Inc. $44,468 19 payments
  2. Boehringer Ingelheim International GmbH $2,984 1 payment
  3. Novo Nordisk AS $1,269 5 payments
  4. Eli Lilly and Company $570 1 payment

Records

183 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Endocrinology in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record